PlexusDx compounded semaglutide, at $189/mo month-to-month, or from $149/mo on the 6-month plan, delivers these benefits with proper medical oversight and baseline kidney function assessment
Call us at (760) 875-0531 anytime
In the US the drug was approved in 2023 to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in patients with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors
Clinical evidence supporting GLP-1based therapies is well documented in peer-reviewed medical literature, including studies available on PubMed, which highlight significant weight reduction and metabolic improvement with GLP-1 receptor agonists
Journal of Nutrition and Metabolism, 2016
Many of its effects are mediated through a hormone called IGF-1 (Insulin-Like Growth Factor 1) , which is primarily produced in the liver in response to GH signaling